Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F20%3AA21025RF" target="_blank" >RIV/61988987:17110/20:A21025RF - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/20:E0108506
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.2736" target="_blank" >https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.2736</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/hon.2736" target="_blank" >10.1002/hon.2736</a>
Alternative languages
Result language
angličtina
Original language name
Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort
Original language description
Multiple myeloma (MM) is the second most common blood cancer caused by the uncontrolled proliferation of clonal plasma cells. Despite recent advances in treatment, a majority of patients eventually relapse and die because of progressive disease (PD). Thus, the development of modern molecules with novel mechanisms of action is needed. The overexpression of antiapoptotic proteins (ie, Bcl‐2, Bcl‐XL, Mcl‐1) represents one of the hallmarks of cancer that favors tumor cell survival. It has been demonstrated that a subset of MM is Bcl‐2 dependent. These are especially those harboring the t(11;14)—molecular subgroup which is associated with a high expression of Bcl‐2 and a low expression of Bcl‐XL and Mcl‐1.1, 2 The presence of translocation t(11;14) is present in 15%‐20% of newly diagnosed MM3 and even up in 50% of primary plasma cell leukemia.4
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
HEMATOLOGICAL ONCOLOGY
ISSN
0278-0232
e-ISSN
1099-1069
Volume of the periodical
38
Issue of the periodical within the volume
3
Country of publishing house
GB - UNITED KINGDOM
Number of pages
3
Pages from-to
412-414
UT code for WoS article
000527833100001
EID of the result in the Scopus database
—